News | Clinical Decision Support | September 09, 2015

DataSpeaks' proprietary algorithm can generate scores suggesting dose adjustments and medication switches via patient-generated and sensor data

DataSpeaks, SRI International, license, SIMA, clinical decision support

September 9, 2015 — SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.

The SIMA algorithm can transform multiple streams of patient-generated and sensor data (from wearable or implantable devices) into actionable, integrated, and personalized assessments of risks (harms) and benefits for drugs in a patient's regimen. The resulting scores may be used in the future to quickly alert healthcare practitioners about potential needs for dose adjustments and medication switches.

"The unique SIMA analytic software has the capacity to synergize with other SRI platforms as a component of an integrated enterprise system designed to enhance clinical decision-making, thereby maximizing the likelihood of treatment benefit and minimizing the risk of significant side-effects related to drugs," said David Sahner, M.D., senior director, clinical translation, SRI Biosciences. "This offers the hope of major reductions in morbidity, mortality and the over $7 billion in annual healthcare costs related to the use of potentially inappropriate medications."

The in-licensing of the software was enabled by a grant from the Michigan Economic Development Corporation to establish an inter-institutional Center of Innovation focused on personalized medicine and pharmacotherapy in the elderly.

DataSpeaks' proprietary SIMA algorithm applies to multivariate time series data that are becoming ubiquitous with hospital, home, wearable, implanted, and environmental monitoring devices; apps; electronic diaries; and pill monitors. SIMA yields internally standardized scores that quantify evidence for clinically relevant interactions over time as "edges" in network graphs that are computed from data about individual patients.

Additional potential uses of SIMA include improvement of diagnostic taxonomies that may facilitate better prediction and therapy choices, identification of disease mechanisms and new drug development targets, and use in novel clinical trial designs that do not "wash out" individual patient differences.

For more information: www.dataspeaks.com, www.sri.com


Related Content

News | Digital Pathology

September 13, 2022 — Deciphex, a Dublin, Ireland-based provider of digital pathology software and services, has ...

Time September 13, 2022
arrow
News | Clinical Decision Support

April 22, 2021 — Change Healthcare unveiled InterQual 2021, the latest edition of the company’s flagship clinical ...

Time April 22, 2021
arrow
News | Clinical Decision Support

April 2, 2021 — Elsevier, a global leader in research publishing and information analytics, announced a partnership with ...

Time April 02, 2021
arrow
News | Clinical Decision Support

June 16, 2020 — Philips and The University of Texas MD Anderson Cancer Center announced a collaboration to provide ...

Time June 16, 2020
arrow
News | Clinical Decision Support

March 13, 2020 — IBM Watson Health and EBSCO Information Services (EBSCO) announced a strategic collaboration aimed ...

Time March 13, 2020
arrow
News | Clinical Decision Support

December 26, 2019 — Effective Jan. 1, 2020, new regulations under the Centers for Medicare & Medicaid Services (CMS) ...

Time December 26, 2019
arrow
Videos | Radiology Business

Association for Medical Imaging Management (AHRA) President Chris Tomlinson, CRA, FAHRA, and President-elect Jacqui Rose ...

Time August 02, 2019
arrow
News | Clinical Decision Support

On June 30, 2019, the Centers for Medicare & Medicaid Services (CMS) announced the Johns Hopkins University School of Medicine has been designated a qualified provider-led entity (qPLE). This allows Johns Hopkins to develop criteria that meet the requirements of the federal Protecting Access to Medicare Act (PAMA) of 2014 when ordering diagnostic imaging tests such as computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and nuclear imaging in the emergency department and ambulatory settings.

Time July 18, 2019
arrow
News | Digital Pathology

July 16, 2019 — Computational pathology company Paige announced the publication of an article in Nature Medicine ...

Time July 16, 2019
arrow
News | Ultrasound Women's Health

Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Time July 11, 2019
arrow
Subscribe Now